Entrepreneurship accelerates at the UB and adds 23 start-ups

Covid has been a shock to entrepreneurship at the University of Barcelona, ​​explains José Conde, head of business creation at the Fundació Bosch i Gimpera, the university's technology transfer office.

NewsEditor
NewsEditor
14 September 2022 Wednesday 09:12
8 Reads
Entrepreneurship accelerates at the UB and adds 23 start-ups

Covid has been a shock to entrepreneurship at the University of Barcelona, ​​explains José Conde, head of business creation at the Fundació Bosch i Gimpera, the university's technology transfer office. "The pandemic allowed many researchers to stop and review what part of their work could have a practical application and not just academic relevance," he noted. The University, he explained, today has 23 spin-offs and closed last year with 22, which had a turnover of 9.35 million euros, 31% more than the previous year, and a record in the annals of the university. Four of these firms already invoice more than one million euros: Enantia, Biocontrol Technologies, Cytes Biotechnologies and Qilimanjaro Quantum Tech.

Conde explains that last year at the UB two new emerging companies, Oniria Therapeutics and Reveal Genomics, were created. “We also have failures: nine of our holdings have closed. In many cases, a start-up has a binary outcome: if the clinical trials of a drug go well, it could be sold to a large pharmaceutical company for commercialization. On the other hand, if the clinical studies fail, the start-up has to close”.

Most of the companies born from the UB are from the health and biology sector “where we have a high level of research that is driven because there is a mature ecosystem to promote these spin-offs, such as venture capital funds”. In addition, other sectors such as Deep Tech or food are growing strongly.

"We hope that this economic impact will increase," acknowledged Conde. The growth of its investees will contribute to this, but also an increase in the desire to undertake by researchers. “We already have examples of success, which serve as references; support resources, such as incubators and accelerators, and specific training, for example with the support of Barcelona Activa, to design proofs of concept”.

The university participates in the companies of its researchers through Cultura Innovadora i Científica SL, a trading company that it created in 2003. The management of the participating companies is carried out by the Bosch i Gimpera Foundation, the office that coordinates the entire relationship of the university with the business world.

The UB company that billed the most money last year was Enantia, a chemical firm created in 2003 that develops processes for the preparation of active pharmaceutical ingredients. In second position is Biocontrol Technologies, which develops biological control agents for crop diseases (fungi, bacteria, etc.). Behind it is Cytes Biotechnologies, which offers services for the isolation, maintenance and distribution of liver cells, so that they can be used to research and develop new drugs. The fourth most powerful, Qilimanjaro Quantum Tech, develops quantum computers and algorithmic solutions

Las participadas de la Universitat de Barcelona son actualmente Accure Therapeutics (2020); Advanced Nanotechnologies (2012); Aigecko Technologies (2020); Biocontrol Technologies (2004); Bluephage (2016); Braingaze (2013); Colorsensing (2018); Cytes Biotechnologies (2015); DapCom Data Services (2013); DBgen Ocular Genomics (2018); Enantia (2003); Gate2Brain (2020); Impetux Optics (2012); Kumux (2017); Mind and Identity (2020); Neurekalab (2019); Nimble Diagnostics (2022), Nostrum Biodiscovery (2015); Oniria Therapeutics (2021); Qilimanjaro Quantum Tech (2019); Reveal Genomics (2021); Smalle Technologies (2012) y Virtual Bodyworks (2015).

Comments

Warning!

You have to login for comment. If you are not a member? Register now.

Login Sign Up